EISAI INC.

๐Ÿ‡บ๐Ÿ‡ธUnited States
Ownership
-
Employees
-
Market Cap
-
Website

A Phase I Open Label Study of E7974 Administered on a Day 1 of 21-Day Cycle In Patients With Advanced Solid Tumors

Phase 1
Completed
Conditions
Interventions
First Posted Date
2005-09-14
Last Posted Date
2013-05-22
Lead Sponsor
Eisai Inc.
Target Recruit Count
40
Registration Number
NCT00165802
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Sylvester Comprehensive Cancer Center - University of Miami, Miami, Florida, United States

๐Ÿ‡บ๐Ÿ‡ธ

Cancer Institute Of New Jersey, New Brunswick, New Jersey, United States

Maintenance Intermittent Therapy for Symptomatic GERD Patients

Phase 2
Completed
Conditions
Interventions
First Posted Date
2005-09-14
Last Posted Date
2013-05-20
Lead Sponsor
Eisai Inc.
Target Recruit Count
200
Registration Number
NCT00165841
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Quality Care Medical Center Inc., Vista, California, United States

Efficacy and Safety of Donepezil Hydrochloride (Aricept) in Vascular Dementia

Phase 4
Completed
Conditions
Interventions
First Posted Date
2005-09-14
Last Posted Date
2012-05-04
Lead Sponsor
Eisai Inc.
Target Recruit Count
36
Registration Number
NCT00165763
Locations
๐Ÿ‡ต๐Ÿ‡ญ

Memory Center, Quezon, Manila, Philippines

๐Ÿ‡ต๐Ÿ‡ญ

Subic Bay Medical Center, Olongapo, Zambales, Philippines

A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease

First Posted Date
2005-09-14
Last Posted Date
2011-10-05
Lead Sponsor
Eisai Inc.
Target Recruit Count
26
Registration Number
NCT00165672

Donepezil Hydrochloride (E2020) in Dementia Associated With Cerebrovascular Disease

Phase 3
Completed
Conditions
First Posted Date
2005-09-14
Last Posted Date
2011-04-01
Lead Sponsor
Eisai Inc.
Target Recruit Count
974
Registration Number
NCT00165737
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Neurological Associate of Albany PC, Albany, New York, United States

๐Ÿ‡บ๐Ÿ‡ธ

St. Francis Medical Center, Peoria, Illinois, United States

๐Ÿ‡บ๐Ÿ‡ธ

University of Texas Mental Sciences Institute, Houston, Texas, United States

and more 2 locations

A Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations

Phase 2
Completed
Conditions
First Posted Date
2005-09-14
Last Posted Date
2015-06-02
Lead Sponsor
Eisai Inc.
Target Recruit Count
75
Registration Number
NCT00165789
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Raleigh Neurology Associates, Southfield, Michigan, United States

๐Ÿ‡บ๐Ÿ‡ธ

Agape Medical Research Center, Piscataway, New Jersey, United States

๐Ÿ‡บ๐Ÿ‡ธ

Clinical Trials Incorporated, Little Rock, Arkansas, United States

and more 6 locations

Efficacy and Safety Study of E2007 in Migraine Prophylaxis

Phase 2
Completed
Conditions
Interventions
First Posted Date
2005-09-12
Last Posted Date
2015-06-08
Lead Sponsor
Eisai Inc.
Target Recruit Count
206
Registration Number
NCT00154063
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Investigational Site, Houston, Texas, United States

๐Ÿ‡บ๐Ÿ‡ธ

Elkind Headache Center, Mount Vernon, New York, United States

E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures

Phase 2
Completed
Conditions
First Posted Date
2005-09-05
Last Posted Date
2015-11-03
Lead Sponsor
Eisai Inc.
Registration Number
NCT00144690
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Clinical Trials, Detroit, Michigan, United States

๐Ÿ‡บ๐Ÿ‡ธ

Dept. of Neuro Surgery, Little Rock, Arkansas, United States

๐Ÿ‡บ๐Ÿ‡ธ

Vanderbilt University Medical Ctr., Nashville, Tennessee, United States

and more 2 locations

Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With Rabeprazole

Phase 2
Completed
Conditions
First Posted Date
2005-08-22
Last Posted Date
2009-12-03
Lead Sponsor
Eisai Inc.
Target Recruit Count
111
Registration Number
NCT00132496
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Marshall University, Huntington, West Virginia, United States

๐Ÿ‡บ๐Ÿ‡ธ

Professional Clinical Research, Cadillac, Michigan, United States

๐Ÿ‡บ๐Ÿ‡ธ

University of Pediatrics, Mason, Ohio, United States

and more 22 locations

Effects of Combination Therapy With Alpha-1 Blocker (Bunazosin or Doxazosin) in the Treatment of Patients With Mild to Moderate Essential Hypertension

First Posted Date
2005-08-15
Last Posted Date
2013-05-14
Lead Sponsor
Eisai Inc.
Target Recruit Count
93
Registration Number
NCT00130156
Locations
๐Ÿ‡จ๐Ÿ‡ณ

National Taiwan University Hospital., Taipei, Taiwan

ยฉ Copyright 2024. All Rights Reserved by MedPath